We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) closed the most recent trading day at $311.60, moving +1.56% from the previous trading session. This move lagged the S&P 500's daily gain of 1.83%. At the same time, the Dow added 1.4%, and the tech-heavy Nasdaq gained 0.09%.
Coming into today, shares of the drugmaker had gained 1.25% in the past month. In that same time, the Medical sector lost 6.45%, while the S&P 500 lost 5.51%.
Wall Street will be looking for positivity from Eli Lilly as it approaches its next earnings report date. The company is expected to report EPS of $1.93, down 0.52% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.01 billion, up 3.52% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.99 per share and revenue of $28.82 billion, which would represent changes of -2.08% and +1.75%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% lower within the past month. Eli Lilly is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, Eli Lilly currently has a Forward P/E ratio of 38.38. Its industry sports an average Forward P/E of 12.49, so we one might conclude that Eli Lilly is trading at a premium comparatively.
Investors should also note that LLY has a PEG ratio of 2.08 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.84 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 139, putting it in the bottom 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
Eli Lilly (LLY - Free Report) closed the most recent trading day at $311.60, moving +1.56% from the previous trading session. This move lagged the S&P 500's daily gain of 1.83%. At the same time, the Dow added 1.4%, and the tech-heavy Nasdaq gained 0.09%.
Coming into today, shares of the drugmaker had gained 1.25% in the past month. In that same time, the Medical sector lost 6.45%, while the S&P 500 lost 5.51%.
Wall Street will be looking for positivity from Eli Lilly as it approaches its next earnings report date. The company is expected to report EPS of $1.93, down 0.52% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.01 billion, up 3.52% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.99 per share and revenue of $28.82 billion, which would represent changes of -2.08% and +1.75%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% lower within the past month. Eli Lilly is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, Eli Lilly currently has a Forward P/E ratio of 38.38. Its industry sports an average Forward P/E of 12.49, so we one might conclude that Eli Lilly is trading at a premium comparatively.
Investors should also note that LLY has a PEG ratio of 2.08 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.84 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 139, putting it in the bottom 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.